FGP
Freestone Grove Partners Portfolio holdings
AUM
$15.6B
Turnover
60.27%
1-Year Est. Return
27.39%
This Fund
S&P 500
This Quarter
Est. Return
+0.81%
1 Year Est. Return
+27.39%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$14.2B
AUM Growth
+$326M
(+2.4%)
Cap. Flow
+$206M
Cap. Flow
% of AUM
1.46%
Top 10 Holdings %
Top 10 Hldgs %
19%
Holding
1,229
New
515
Increased
214
Reduced
228
Closed
267
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.1
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Citigroup
C
|
+$134M |
| 2 |
Pinnacle Financial Partners Inc
PNFP
|
+$120M |
| 3 |
KKR & Co
KKR
|
+$113M |
| 4 |
Mondelez International
MDLZ
|
+$103M |
| 5 |
AXIS Capital
AXS
|
+$97.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$303M |
| 2 |
Boston Scientific
BSX
|
+$127M |
| 3 |
Lennar Class A
LEN
|
+$95.9M |
| 4 |
Martin Marietta Materials
MLM
|
+$94.6M |
| 5 |
Colgate-Palmolive
CL
|
+$92M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.98% |
| 2 | Technology | 14.39% |
| 3 | Miscellaneous | 12.72% |
| 4 | Industrials | 12.27% |
| 5 | Healthcare | 11.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
501
ESAB
ESAB
$4.01B
| $887K | 0.01% |
9,176
+5,720
| +166% | +$663K |
2025 Q4
1 quarter
|
|
502
Belden
BDC
$4.07B
| $882K | 0.01% |
7,684
+1,962
| +34% | +$247K |
2025 Q1
4 quarters
|
|
503
Goosehead Insurance
GSHD
$1.06B
| $879K | 0.01% |
20,599
-167,672
| -89% | -$9.38M |
2025 Q4
1 quarter
|
|
504
Nucor
NUE
$58.3B
| $869K | 0.01% |
+5,137
| New | +$895K |
2026 Q1
0 quarters
|
|
505
TripAdvisor
TRIP
$1.05B
| $867K | 0.01% |
+81,374
| New | +$948K |
2026 Q1
0 quarters
|
|
506
The Mosaic Company
MOS
$6.04B
| $841K | 0.01% |
32,965
-69,545
| -68% | -$1.91M |
2025 Q4
1 quarter
|
|
507
Cal-Maine
CALM
$2.95B
| $838K | 0.01% |
10,592
-4,230
| -29% | -$347K |
2025 Q4
1 quarter
|
|
508
BancFirst
BANF
$3.59B
| $837K | 0.01% |
+7,712
| New | +$857K |
2026 Q1
0 quarters
|
|
509
Donaldson
DCI
$10.1B
| $827K | 0.01% |
+9,739
| New | +$941K |
2026 Q1
0 quarters
|
|
510
Pacira BioSciences
PCRX
$1.45B
| $823K | 0.01% |
36,422
-410
| -1% | -$9.11K |
2025 Q4
1 quarter
|
|
511
Upbound Group
UPBD
$900M
| $818K | 0.01% |
45,314
+26,152
| +136% | +$510K |
2025 Q3
2 quarters
|
|
512
Zebra Technologies
ZBRA
$17.8B
| $812K | 0.01% |
3,883
+2,227
| +134% | +$523K |
2024 Q4
5 quarters
|
|
513
Cirrus Logic
CRUS
$5.43B
| $810K | 0.01% |
+5,602
| New | +$754K |
2026 Q1
0 quarters
|
|
514
TG Therapeutics
TGTX
$8.32B
| $810K | 0.01% |
24,379
+9,633
| +65% | +$287K |
2025 Q4
1 quarter
|
|
515
HealthEquity
HQY
$7.43B
| $809K | 0.01% |
+9,683
| New | +$794K |
2026 Q1
0 quarters
|
|
516
Turning Point Brands
TPB
$1.16B
| $807K | 0.01% |
+9,303
| New | +$1.04M |
2026 Q1
0 quarters
|
|
517
Kiniksa Pharmaceuticals
KNSA
$6.15B
| $802K | 0.01% |
+16,660
| New | +$738K |
2026 Q1
0 quarters
|
|
518
Utz Brands
UTZ
$1.27B
| $797K | 0.01% |
+100,598
| New | +$935K |
2026 Q1
0 quarters
|
|
519
International Seaways
INSW
$5.88B
| $790K | 0.01% |
10,843
+1,994
| +23% | +$128K |
2024 Q4
5 quarters
|
|
520
Sensata Technologies
ST
$5.99B
| $787K | 0.01% |
22,354
+858
| +4% | +$30.4K |
2025 Q3
2 quarters
|
|
521
Union Pacific
UNP
$170B
| $780K | 0.01% |
3,216
-13,842
| -81% | -$3.39M |
2024 Q4
5 quarters
|
|
522
Exponent
EXPO
$3.38B
| $778K | 0.01% |
+11,925
| New | +$847K |
2026 Q1
0 quarters
|
|
523
Sotera Health
SHC
$5.06B
| $776K | 0.01% |
+54,111
| New | +$898K |
2026 Q1
0 quarters
|
|
524
Skywest
SKYW
$3.59B
| $772K | 0.01% |
8,411
-8,481
| -50% | -$836K |
2025 Q3
2 quarters
|
|
525
Primerica
PRI
$8.57B
| $770K | 0.01% |
3,074
+2,257
| +276% | +$582K |
2025 Q1
4 quarters
|
|
Similar funds
ECM
MIFH
GF
AIM
OTPPB
AA
IWC
Freestone Grove Partners's Q1 2026 Portfolio in Review
As of Q1 2026, Freestone Grove Partners held 1,229 positions worth $14.2B, up 2.4% from $13.8B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Freestone Grove Partners's Q1 2026 filing shows 515 new, 214 increased, 228 reduced and 267 closed positions. Its largest new stake was Citigroup: 1,180,436 shares worth $134M. The largest sale was iShares Core S&P 500 ETF, an estimated $303M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 15% a quarter earlier, followed by Technology and Miscellaneous.
- Freestone Grove Partners's largest Q1 2026 buy was Citigroup: 1,180,436 shares worth $134M.
- Freestone Grove Partners added most to AXIS Capital in Q1 2026, an estimated $97.1M increase.
- Freestone Grove Partners's biggest Q1 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $303M.
- Freestone Grove Partners fully exited Boston Scientific in Q1 2026, selling an estimated $127M.
- Freestone Grove Partners's ten largest holdings make up 19% of its $14.2B portfolio in Q1 2026.
- Freestone Grove Partners opened 515 new positions and closed 267 in Q1 2026.
- Freestone Grove Partners's portfolio value rose 2.4% quarter-over-quarter to $14.2B.
Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.